Itraconazole versus propranolol: therapeutic and pharmacologic effect on serum angiopoietin-2 in patients with infantile hemangioma.
Angiogenesis
biomarkers
differentiation
human model
proliferation
Journal
The Journal of dermatological treatment
ISSN: 1471-1753
Titre abrégé: J Dermatolog Treat
Pays: England
ID NLM: 8918133
Informations de publication
Date de publication:
Feb 2022
Feb 2022
Historique:
pubmed:
2
11
2019
medline:
16
2
2022
entrez:
1
11
2019
Statut:
ppublish
Résumé
The initial recommendation propranolol usage in managing infantile hemangioma was in 2008 followed by various researches assessing the dosage, efficacy, and other parameters. Itraconazole is a world-wide tolerated antifungal but only a few studies have focused on its assessment in the treatment of infantile hemangiomas (IH). This study aimed to investigate the newly proposed antifungal drug ICZ and characterize different aspects of its usage as an antiangiogenic drug. This was an interventional clinical trial to assess the efficacy of ICZ versus propranolol in the treatment of infantile hemangioma with studying the change in serum angiopoietin 2 (Ang2). A total of 36 pediatric patients were divided into two equal groups: firstly treated with oral itraconazole and secondly treated by oral propranolol. Response to treatment was observed using a modified IH score. In itraconazole-treated infants, good response was observed in 44.4% of the patients. This was slightly higher than the propranolol group which showed 22.2% with good response. We observed a decrease in serum ang2 level after usage of ICZ and propranolol and the change in serum Ang2 level before and after treatment in each group was statistically significant ( Oral itraconazole can be an equivalent option for oral propranolol while safer and shorter treatment periods.
Sections du résumé
BACKGROUND
BACKGROUND
The initial recommendation propranolol usage in managing infantile hemangioma was in 2008 followed by various researches assessing the dosage, efficacy, and other parameters. Itraconazole is a world-wide tolerated antifungal but only a few studies have focused on its assessment in the treatment of infantile hemangiomas (IH).
OBJECTIVE
OBJECTIVE
This study aimed to investigate the newly proposed antifungal drug ICZ and characterize different aspects of its usage as an antiangiogenic drug.
METHODS
METHODS
This was an interventional clinical trial to assess the efficacy of ICZ versus propranolol in the treatment of infantile hemangioma with studying the change in serum angiopoietin 2 (Ang2). A total of 36 pediatric patients were divided into two equal groups: firstly treated with oral itraconazole and secondly treated by oral propranolol.
RESULTS
RESULTS
Response to treatment was observed using a modified IH score. In itraconazole-treated infants, good response was observed in 44.4% of the patients. This was slightly higher than the propranolol group which showed 22.2% with good response. We observed a decrease in serum ang2 level after usage of ICZ and propranolol and the change in serum Ang2 level before and after treatment in each group was statistically significant (
CONCLUSION
CONCLUSIONS
Oral itraconazole can be an equivalent option for oral propranolol while safer and shorter treatment periods.
Identifiants
pubmed: 31668109
doi: 10.1080/09546634.2019.1687822
doi:
Substances chimiques
Adrenergic beta-Antagonists
0
Angiopoietin-2
0
Antifungal Agents
0
Itraconazole
304NUG5GF4
Propranolol
9Y8NXQ24VQ
Types de publication
Clinical Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM